MaxCyte, Inc. has launched ExPERT DTx, a 96-well electroporation platform designed to accelerate discovery and development of cell-based therapeutics. The system allows researchers to transfect primary cells and cell lines with minimal stress, enabling consistent and scalable results for drug discovery applications.

The platform processes up to 96 samples in a three-minute run, with 12 detachable 8-well strips that can be run in parallel with unique parameters for different cell and cargo combinations. This modular design is intended to reduce variability between wells, streamline workflows and simplify scale-up to larger transfection volumes or cGMP-compliant manufacturing.

The ExPERT DTx includes two software packages. The DTx Software controls and monitors the instrument, while DTx Designer allows users to design experiments remotely and upload workflows when the system is available, maximising lab efficiency for multiple back-to-back experiments.

Maher Masoud, chief executive officer of MaxCyte, said: “This platform provides researchers with deep insights into their experiments, helping them investigate the underlying biology of a cellular system before scaling up operations. We’ve developed this product around our customers’ needs, giving them the flexibility needed for research while delivering reproducible results with high cell viability.”

The system has been validated for a range of applications, including protein production, cell and gene therapy development, and preclinical research, and allows transfer of optimised processes to other ExPERT instruments without workflow re-optimisation.

ExPERT DTx aims to support researchers in addressing variability in electroporation workflows and accelerate discovery programmes across academic and commercial laboratories.